Electrocore ECOR 深 沪
等待开盘 02-05 09:30:00 美东时间
5.55
-0.520
-8.57%
华盛通- 最 高6.11
- 今 开6.09
- 成交量 3.24万股
- 最 低 5.51
- 昨 收 6.07
- 总市值 4208.79万
- 52周最高 19.49
- 市盈率 静 --
- 换手率 0.43%
- 52周最低 4.16
- 委 比 0.00%
- 总股本 758.34万
- 历史最高 303.75
- 量 比 0.52
- 振 幅 9.88%
- 历史最低 2.925
- 每 手 1
- 风险率 3.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 斯伦贝谢、SouthState Bank、西屋制动、特里科银行获多家大行上调目标价；苹果、meta、微软等绩前遭下调目标价
今日重点评级关注：Oppenheimer：维持Pelthos Therapeutics"跑赢大市"评级，目标价从57美元升至60美元；Small Cap Consumer Research：维持Lands' End"买入"评级，目标价从20美元升至45美元
01-27 10:02
HC Wainwright & Co. Maintains Buy on electroCore, Lowers Price Target to $18
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains electroCore (NASDAQ:ECOR) with a Buy and lowers the price target from $25 to $18.
01-26 20:36
U.S. RESEARCH ROUNDUP-CACI International, First Citizens Bancshares, Teledyne Technologies
U.S. RESEARCH ROUNDUP-CACI International, First Citizens Bancshares, Teledyne Technologies Jan 26 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including CACI International, First Citizens Bancshares and Teledyne Technologies, o
01-26 15:22
electroCore Anticipates Reporting FY25 Revenue Of ~$31.8M-$32M; Estimates Q4 Revenue To Be ~$9M-$9.2M
Record revenue of approximately $31.8 - $32.0 million for full-year 2025 and approximately $9.0 - $9.2 million for the three months ended December 31, 2025 Revenue growth of approximately 26% over full-year
01-20 21:09
electroCore Provides Preliminary Full-Year 2025 Business Update; Expects ~26% Revenue Growth to ~$31.8–$32.0 Million
ElectroCore Inc., a bioelectronic technology company, provided preliminary financial guidance for 2025, projecting full-year revenue of $31.8 - $32.0 million, reflecting a 26% increase from 2024. Fourth-quarter revenue is anticipated at $9.0 - $9.2 million, up 30% year-over-year. The company ended 2025 with $11.6 million in cash, down from $13.2 million as of September 2025. A detailed update will be shared during the Q4 and full-year earnings ca...
01-20 13:00
TAC-STIM Demonstrates Significant Performance Improvements in Active-Duty United States Air Force Airmen
electroCore, Inc. announced the publication of a peer-reviewed paper demonstrating that its TAC-STIM non-invasive vagal nerve stimulation device enhances mood, task performance, and learning in high-stress military training environments. The study, involving 70 active-duty Air Force trainees, found statistically significant reductions in stress and improvements in energy, skill, and objective performance metrics among tVNS users. Results highligh...
2025-12-02 13:00
electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
electroCore, Inc. announced that its management will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on November 20, 2025. The event will include one-on-one meetings with investors, which can be scheduled through Canaccord Genuity sales representatives or by contacting electroCore's Investor Relations at ecor@fnkir.com.
2025-11-10 21:05
electroCore Sees FY2025 Sales $31.500M-$32.500M vs $30.749M Est
electroCore (NASDAQ:ECOR) sees FY2025 sales of $31.500 million-$32.500 million vs $30.749 million analyst estimate.
2025-11-06 08:00
Electrocore Finalizes Stock Sale to Settle Legal Fees
Electrocore ( ($ECOR) ) has issued an announcement. On September 30, 2025, Elec...
2025-10-04 04:58
gammaCore® Non-Invasive Vagus Nerve Stimulation (nVNS) as an Adjunctive Treatment Associated with Improvements in Persistent Post-Concussion Symptoms
ElectroCore's gammaCore device shows promise in reducing symptoms of mild traumatic brain injury (mTBI), according to a study published in *Frontiers in Neurology*. The research involving 102 patients found significant improvements in 16 out of 22 symptom categories, with 34% of participants reporting meaningful relief in at least half their symptoms. Notably, benefits were observed regardless of the time since injury, and no adverse device-relat...
2025-09-30 12:00
